Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Brickell Biotech, Inc. (BBI)
Newly released Crypto mining rig for Brickell Biotech, Inc. coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Brickell (BBI) Reports Q2 Loss, Tops Revenue Estimates
2 days ago | Zacks Investment Research
Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2 days ago | GlobeNewsWire
Brickell (BBI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
a week ago | Zacks Investment Research
Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021
2 weeks ago | GlobeNewsWire
Why Brickell Biotech Shares Are Trading Lower Today
3 weeks ago | Benzinga
BBI Stock Fell Over 20% Pre-Market: Why It Happened
3 weeks ago | Pulse2
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
3 weeks ago | GlobeNewsWire
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
3 weeks ago | GlobeNewsWire
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
a month ago | GlobeNewsWire
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
2 months ago | GlobeNewsWire

About:

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company’s lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

13

Address:

Brickell Biotech, Inc. 5777 Central Avenue Suite 102 Boulder CO 80301 United States

Website:

http://www.brickellbio.com

Phone:

720-505-4755

Leave a comment

Your email address will not be published. Required fields are marked *